22.418 articles found

COMBINED THERAPY FOR THE TREATMENT OF PARKINSON'S DISEASE

DI PAOLO THERESE.

· 2004-05-28

SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE.

CORINNA SUNDERMANN.

· 2004-05-28

Treatment of neurodegenerative disease through intracranial delivery of siRNA

KAEMMERER WILLIAM F.

· 2004-05-25

Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.

Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P.

Brain · 2004-05-20

DOI: 10.1093/brain/awh190PMID: 15155524

Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.

Pöpperl G, Tatsch K, Ruzicka E, Storch A, Gasser T, Schwarz J.

J Neural Transm (Vienna) · 2004-05-12

DOI: 10.1007/s00702-004-0147-6PMID: 15254792

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

Onofrj M, Thomas A, Vingerhoets F, Martin W, Giménez-Roldán S, Azulay JP, Bernhard G, Schmidt W, Markabi S.

J Neural Transm (Vienna) · 2004-05-12

DOI: 10.1007/s00702-004-0149-4PMID: 15254793

Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).

Morrison CE, Borod JC, Brin MF, Hälbig TD, Olanow CW.

J Neural Transm (Vienna) · 2004-05-12

DOI: 10.1007/s00702-004-0145-8PMID: 15480842

Methods and devices for the treatment of neurological and physiological disorders

MISCHE HANS A.

· 2004-05-11

Methods and devices for the treatment of neurological and physiological disorders

MISCHE HANS A.

· 2004-05-11

Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease

SCHEYER RICHARD D, SORENSEN STEPHEN M, HITCHCOCK JANICE M.

· 2004-05-03

Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.

Müller T, Benz S, Börnke C, Przuntek H.

Acta Neurol Scand · 2004-05-01

DOI: 10.1046/j.1600-0404.2003.00231.xPMID: 15080862

Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.

Joyce JN, Der TC, Renish L, Osredkar T, Hagner D, Reploge M, Sakakibara S, Ueda S.

Exp Neurol · 2004-05-01

DOI: 10.1016/j.expneurol.2004.01.012PMID: 15081599